How Investors May Respond To Cadre Holdings (CDRE) Pentagon Contract For Blast‑Exposure Monitoring Systems

• Cadre Holdings’ subsidiary Med-Eng LLC previously secured a five-year, US$50,000,000 contract with the US Department of Defense to supply blast‑exposure monitoring systems for tracking overpressure events in combat and training settings, with first deliveries planned for 2026.
• This award deepens Cadre’s ties with the Pentagon and highlights its growing role in advanced protective technologies that support frontline military personnel.
• We’ll now examine how this multi‑year Pentagon contract could influence Cadre Holdings’ investment narrative and its defense‑focused growth outlook.

We've found 10 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Cadre Holdings Investment Narrative Recap

To own Cadre Holdings, you need to believe in sustained demand for specialized protective and safety equipment across defense, law enforcement, and nuclear markets, supported by disciplined capital allocation and M&A. The new US$50,000,000 Med-Eng contract slightly reduces timing uncertainty around defense orders in the near term, but funding and procurement shifts across broader government customers still look like the key short term catalyst and the biggest ongoing risk.

The Med-Eng award also sits alongside Cadre’s consistent quarterly dividend of US$0.095 per share in 2025, which signals a focus on returning cash to shareholders while funding growth. For investors, that combination of contracted defense work and steady cash distributions can sharpen the lens on how resilient future government budgets and procurement cycles need to be for the story to hold.

Yet investors should also be aware that heavy reliance on government and law enforcement budgets could become a headwind if procurement priorities suddenly shift or…

Read the full narrative on Cadre Holdings (it's free!)

Cadre Holdings' narrative projects $787.2 million revenue and $74.8 million earnings by 2028. This requires 11.2% yearly revenue growth and about a $36.7 million earnings increase from $38.1 million today.

Uncover how Cadre Holdings' forecasts yield a $48.50 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members see fair value for Cadre between US$48.50 and US$67.25, based on 2 independent views. Set those differing opinions against the concentration of revenue in government contracts and you can start to see why it pays to compare several perspectives before deciding how this business might fit into your portfolio.

Explore 2 other fair value estimates on Cadre Holdings - why the stock might be worth just $48.50!

Build Your Own Cadre Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Cadre Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cadre Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cadre Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com